Drug Topics

APRIL 6, 2024

Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee, talks about why pharmacies should open their own Medicare-focused insurance agency and what steps and preparations they can take to ensure a successful launch and operation.

Independent Pharmacies 144

Independent Pharmacies Insurance 144

STAT

APRIL 6, 2024

ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity, diabetes, and a common type of heart failure, boosting Novo’s attempt to get the popular drug approved for yet another usage beyond weight loss. The study, being presented here on Saturday at the American College of Cardiology conference and published in the New England Journal of Medicine , reports results from the second large trial Novo has conducted on Wegovy in heart fai

FDA 137

FDA 137

Drug Topics

APRIL 6, 2024

At AAP 2024, Kathy Campbell, PharmD, discussed obstacles that pharmacies may face when transitioning to a wellness-focused approach.

144

144

STAT

APRIL 6, 2024

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “For national security, the U.S.

85

85

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Topics

APRIL 6, 2024

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

144

144

Pharmacy Times

APRIL 6, 2024

This is the fifth indication for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo and AstraZeneca) approved by the FDA.

FDA 65

FDA 65